Recently, the HealthCare unit of Bayer ( BAYRY ) announced that its oncology drug Stivarga (regorafenib) will be reviewed on a priority basis by the US Food and Drug Administration
View the original here:
Priority FDA Review for Stivarga – Analyst Blog